Get the Stockscreener App
69.80
0.07%
-0.05
After Hours:
69.61
-0.19
-0.27%
Avidity Biosciences Inc stock is traded at $69.80, with a volume of 6.03M.
It is down -0.07% in the last 24 hours and up +48.51% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$69.85
Open:
$69.77
24h Volume:
6.03M
Relative Volume:
1.21
Market Cap:
$10.18B
Revenue:
$10.73M
Net Income/Loss:
$-455.74M
P/E Ratio:
-19.62
EPS:
-3.5569
Net Cash Flow:
$-502.70M
1W Performance:
-0.29%
1M Performance:
+48.51%
6M Performance:
+116.77%
1Y Performance:
+66.71%
1-Day Range:
$69.75
$69.88
1-Week Range:
$69.50
$70.00
52-Week Range:
$21.51
$72.05
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
69.80 | 10.26B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Roth Capital | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Bernstein | Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Jun-11-25 | Initiated | Raymond James | Strong Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Visual analytics tools that track Avidity Biosciences Inc. performanceBreakout Watch & Weekly High Return Stock Forecasts - newser.com
What to expect from Avidity Biosciences Inc. in the next 30 daysJuly 2025 Institutional & Technical Buy Zone Confirmation - newser.com
Using AI based signals to follow Avidity Biosciences Inc.July 2025 Fed Impact & Free Long-Term Investment Growth Plans - newser.com
Will Avidity Biosciences Inc. stock sustain high P E ratiosJuly 2025 Summary & Comprehensive Market Scan Reports - newser.com
What Wall Street predicts for Avidity Biosciences Inc. stock price2025 Historical Comparison & Reliable Price Breakout Signals - newser.com
Is Avidity Biosciences Inc. showing signs of accumulationMarket Activity Summary & Consistent Income Trade Recommendations - newser.com
How Avidity Biosciences Inc. stock performs in weak economyJuly 2025 Momentum & Low Drawdown Momentum Trade Ideas - newser.com
How Avidity Biosciences Inc. stock compares to growth peersQuarterly Market Summary & Free High Return Stock Watch Alerts - newser.com
Using R and stats models for Avidity Biosciences Inc. forecastingMarket Weekly Review & Safe Capital Growth Trade Ideas - newser.com
Will Avidity Biosciences Inc. stock attract more institutional investorsTrade Entry Summary & Reliable Volume Spike Trade Alerts - newser.com
Can Avidity Biosciences Inc. stock deliver sustainable ROEQuarterly Market Summary & Free High Return Stock Watch Alerts - newser.com
Why Avidity Biosciences Inc. stock attracts global investorsMarket Trend Report & Capital Protection Trade Alerts - newser.com
Real time alert setup for Avidity Biosciences Inc. performanceWeekly Trade Review & Capital Efficiency Focused Strategies - newser.com
Why Avidity Biosciences Inc. stock is popular among millennialsWeekly Trend Summary & Community Driven Trade Alerts - newser.com
Applying Wyckoff theory to Avidity Biosciences Inc. stockAnalyst Upgrade & Free Real-Time Market Sentiment Alerts - newser.com
Short interest data insights for Avidity Biosciences Inc.Earnings Growth Summary & Verified Short-Term Plans - newser.com
Will Avidity Biosciences Inc. stock deliver long term returnsMarket Trend Review & Smart Allocation Stock Reports - newser.com
How Avidity Biosciences Inc. stock benefits from strong dollarJuly 2025 Price Swings & High Accuracy Trade Signal Alerts - newser.com
Earnings visualization tools for Avidity Biosciences Inc.Portfolio Growth Summary & Real-Time Sentiment Analysis - newser.com
Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger - Insider Monkey
Can Avidity Biosciences Inc. stock beat market expectations this quarterJuly 2025 Outlook & AI Optimized Trade Strategies - newser.com
Can Avidity Biosciences Inc. stock surprise with earnings upsideJuly 2025 Review & AI Optimized Trade Strategies - newser.com
Exploring Avidity Biosciences (RNA) Valuation Following Recent Share Price Surge - Yahoo Finance
10 Stocks With Easy 20-40% Gains - Insider Monkey
Is Avidity Biosciences Inc. stock ready for breakout2025 Breakouts & Breakdowns & Technical Pattern Based Signals - newser.com
Forecasting Avidity Biosciences Inc. price range with options dataGap Down & Weekly Top Performers Watchlists - newser.com
Pharmaceutical Stocks To Keep An Eye OnOctober 28th - MarketBeat
What momentum shifts mean for Avidity Biosciences Inc.Portfolio Performance Report & High Return Trade Guides - newser.com
Will a bounce in Avidity Biosciences Inc. offer an exitQuarterly Portfolio Report & Verified Momentum Watchlists - newser.com
Best Pharmaceutical Stocks To Follow TodayOctober 27th - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Lowered to "Hold" Rating by Wolfe Research - MarketBeat
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) - Yahoo Finance
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):